The transformation of Chinese pharmaceutical companies

With the beginning of the market reshuffle, the development of pharmaceutical giants has become a consensus within the industry. However, in the domestic pharmaceutical industry, the problems such as too low production capacity and rising costs are still lingering. Chinese pharmaceutical companies are not becoming stronger at the same time they are bigger. In this regard, experts pointed out that under the influence of internal and external environments, Chinese pharmaceutical companies should take advantage of the introduction of good policies to accelerate corporate transformation and upgrading before they can compete in an invincible position.

Market Stress Development Although China's pharmaceutical industry has maintained a high growth rate of over 15% in recent years and is still in an upward trend, at the same time as economic growth, pharmaceutical companies also face many unfavorable factors.

Judging from the external environment, the pharmaceutical regulatory policies in traditional markets such as Europe, the United States and Japan have become increasingly strict, which has affected the export of raw materials in China. In June 2011, the European Union issued a directive that stipulates that all active persons in Europe must issue a written statement from the regulatory authority of the exporting country. Due to the great infeasibility at the implementation level, once the directives are implemented, China's exports of raw materials to the EU will suffer a “disastrous”. According to statistics from China Customs, in the first five months of this year, China's total exports of chemical raw materials accounted for 9.68 billion U.S. dollars, an increase of only 4.9% year-on-year, and the number of exports decreased by 1.58% year-on-year. In the increasingly harsh international regulatory environment, China's pharmaceutical companies are facing a big exam.

On the other hand, the impact of the domestic environment on the industry can not be underestimated. Among the more than 5,000 pharmaceutical industry enterprises in the country, large-scale enterprises account for only 11.7% of the total, and there are no more than 10 companies with annual sales exceeding 10 billion yuan. Under the extensive operating mode of “market-for-technology”, the environmental problems have worsened, and the adverse consequences of “multiple-input and half-volume output” have caused problems in the entire industry that are “more, less, scattered, and chaotic.” Most companies Fall into the risk of being merged or reorganized or eliminated.

Policy Direction of the East Wind Although the market environment for enterprise development is distressed, there are also favorable policies brought about by the policy warming. The “Twelfth Five-Year Plan” pointed out that it will adjust and optimize the industrial structure and promote industrial upgrading as a key task in the pharmaceutical industry. At present, there are dozens of policy support and financial support of 1.037 billion. At the same time, it also provides direction guidance.

At the macro level, the "Industrial Transformation and Upgrading Plan (2011-2015)" pointed out that during the "12th Five-Year Plan" period, the average value-added of the pharmaceutical industry increased by 16% annually; the investment in R&D of key enterprises reached more than 5% of the sales revenue; The sales revenue of 100 companies accounted for more than 50% of the total industry; the energy consumption per unit of industrial added value decreased by 21% compared with the end of the “Eleventh Five-Year Plan”, and the water consumption per unit of industrial added value decreased by 30%. The goals set by the "Twelfth Five-Year Development Plan" of the pharmaceutical industry are more specific. For example, more than 200 large pharmaceutical varieties have been upgraded and upgraded; more than 80 pharmaceutical companies have passed GMP certification from developed countries such as Europe, USA, Japan and the World Health Organization. The proportion of the export of the formulation reached more than 10%.

Under the circumstance that the domestic competitive environment is treacherous and the threshold of foreign markets is too high, Chinese pharmaceutical companies need such a stable, effective, and strong policy environment to resolve the pressures of survival under the current situation and seek development.

Seize the opportunity to seize the opportunity of enterprise layout It is worth noting that the pattern of the world pharmaceutical market is changing, and the trend of regional transfer of international APIs is becoming more and more obvious. For companies, whoever can seize the opportunities will have the future. Some experts pointed out that the road to transformation and upgrading of China's pharmaceutical companies has become clearer. The path for the transfer of bulk APIs to specialty APIs and the transfer of specialty APIs to pharmaceuticals has become increasingly clear.

In fact, looking at the domestic pharmaceutical market, a number of pharmaceutical companies have already begun to show results in transformation and upgrading. For example, Huahai Pharmaceuticals has set up companies and networks in the United States and Europe, and has obtained eight ANDs (simplified new drugs) from the FDA. In 2011, the export volume was 100 million yuan. It is expected that the overseas market sales this year will reach 250 million yuan. Multipliers The effect begins to gradually enlarge.

In addition, experts also stated that enterprises should seize the current opportunity period and do a good job in preparatory work: First, to strengthen the talent and technology reserves; Second, we must strengthen scientific research cooperation, and strive to develop high-tech content, high added value, high market capacity And new products with market occupancy, low consumption, and low pollution; Third, we must adopt the most stringent quality and safety environmental protection measures, and take the road of quality standardization, green safety, and environment-friendly.